A brolucizumab trial shows improvements in visual acuity noninferior to that of aflibercept, with risks of intraocular inflammation for some.

Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...

Reddy's, Jamieson Wellness, Merck, Novartis, Siemens Healthineers and Servier. Kinaxis' AI-powered software allows companies to orchestrate their supply chain network end to end, from strategic ...

There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Under her leadership, the company has achieved record revenues, operating income, and market share in the region. Prior to joining CooperVision in 2013, Olive held senior sales and marketing roles at ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...